1.Exploring the safety and efficacy of GT201 as a first-in-class autologous tumor-infiltrating lymphocyte monotherapy in advanced solid tumors. | Journal of Clinical Oncology (ascopubs.org)
2.Phase 1 study of GT101 as an autologous tumor infiltrating lymphocyte (TIL) therapy in advanced solid tumors. | Journal of Clinical Oncology (ascopubs.org)